SGLT-2 Inhibitors Linked to Lower Epilepsy Risk in Type 2 Diabetes: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-05-21 03:45 GMT | Update On 2025-05-21 07:33 GMT

A recent population-based study published in Diabetes Care suggests that sodium-glucose cotransporter 2 (SGLT-2) inhibitors, commonly prescribed for type 2 diabetes, may also confer neuroprotective benefits by reducing the risk of epilepsy.

The study found that the use of SGLT-2 inhibitors was associated with a 29% lower incidence of epilepsy compared to dipeptidyl peptidase 4 (DPP-4) inhibitors.

SGLT-2 inhibitors function by inhibiting glucose reabsorption in the kidneys, thereby lowering blood glucose levels. Beyond their glycemic effects, these agents have demonstrated cardiovascular and renal benefits.

The observed reduction in epilepsy risk may be attributed to the modulation of neuronal excitability and inflammation, though further research is needed to elucidate the underlying mechanisms.

The study's findings highlight the potential of SGLT-2 inhibitors to provide additional benefits beyond glucose control in individuals with type 2 diabetes. However, the authors note that more studies are necessary to confirm and replicate these results.

Reference:

Houyu Zhao, MD, PhD, et al. (2025). Association Between Use of Sodium–Glucose Cotransporter 2 Inhibitors and Epilepsy: A Population-Based Study Using Target Trial Emulation. Diabetes Care, 48(5), 827–835. https://doi.org/10.2337/dc24-2532

Article Source : Diabetes Care

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

SGLT-2 Inhibitors Linked to Lower Epilepsy Risk in Type 2 Diabetes: Study

Similar News

Study Identifies Lipid Accumulation Product as Strongest Predictor of Diabetes Risk in Visceral Obesity

Osteosarcopenia in Prediabetic Adults Linked to Nearly 3-Fold Higher Osteoarthritis Risk: NHANES Study

Medical Bulletin 05/Jul/2025

Investigational GLP-1 Receptor Agonist effective in Lowering HbA1c in Early Type 2 Diabetes: NEJM

Could Your Saliva Predict Diabetes Risk? Study Finds Out

Early Infections and Obesity in Boys May Reduce Key Male Hormone: Study Suggests

Can Lifestyle Changes Really Prevent Diabetes? Study Provides Insights

Renal Dysfunction Raises Risk of Vertebral Fractures in T2DM Patients, reveals study